- Home
- AMST vs APRE Comparison
AMST vs APRE Comparison
Compare AMST & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMST | APRE |
|---|---|---|
| Founded | 2017 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2M | 8.4M |
| IPO Year | 2020 | 2019 |
Fundamental Metrics
Financial Performance| Metric | AMST | APRE |
|---|---|---|
| Price | $1.83 | $0.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 21.9K | ★ 114.6K |
| Earning Date | 02-05-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 40.46 | 21.22 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $110,459.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.57 | $0.55 |
| 52 Week High | $4.78 | $2.42 |
Technical Indicators
Market Signals| Indicator | AMST | APRE |
|---|---|---|
| Relative Strength Index (RSI) | 46.78 | 43.77 |
| Support Level | $1.61 | $0.72 |
| Resistance Level | $2.14 | $0.95 |
| Average True Range (ATR) | 0.13 | 0.07 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 29.89 | 6.05 |
Price Performance
Historical ComparisonAbout AMST Amesite Inc.
Amesite Inc is an artificial intelligence-driven platform and course designer that rapidly provides customized, high-performance and scalable online products for schools and businesses. The company helps educational institutions and businesses improve learning as their technology partner, delivering a disruptive technology driven by AI and offers a constellation of services that help partners implement new programs, and improve existing ones. Its customers are Enterprises, universities, and K-12 schools.
About APRE Aprea Therapeutics Inc.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.